

PC25144A  
CORRECTIVE FILING RECEIPT



Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
First Class Mail in an envelope addressed to:  
Commissioner for Patents, PO Box 1450,  
Alexandria, VA 22313-1450 on this  
23rd day of June 2004.

s/ Rachel Potash  
Rachel Potash

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**SACHA NINKOVIC, ET AL.**

Serial No.: 10/754,171

Confirmation No.: 8481

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN  
KINASE INHIBITORS FOR ENHANCING THE  
EFFICACY OF ANTI-NEOPLASTIC AGENTS  
AND RADIATION THERAPY

Group Art Unit: 1625

Examiner: Not Yet Assigned

**CORRECTIVE FILING RECEIPT**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attorney for Petitioners hereby petitions the Commissioner for Patents to correct the updated filing receipt mailed May 20, 2004 in the above-identified Non Provisional Application.

In the filing receipt, the domestic priority data is missing. Petitioners request that the Commissioner issue a corrected filing receipt by inserting the following domestic priority data:

**This application claims priority benefits under 35 U.S.C. § 119(e) of a provisional application Serial No. 60/439,396, filed January 9, 2003.**

No fee is believed to be due at this time. If the applicant is in error, please charge all fees related to this filing to Deposit Account No. 500329.

Respectfully submitted,

Date: June 23<sup>rd</sup> '04

Elsa Djuardi  
Elsa Djuardi, Ph.D.  
Attorney For Applicants  
Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6117  
Fax: (858) 678-8233



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/754,171 ✓	01/09/2004 ✓	1625	1658	PC25144A ✓		46	1

28940  
AGOURON PHARMACEUTICALS, INC.  
10350 NORTH TORREY PINES ROAD  
LA JOLLA, CA 92037

CONFIRMATION NO. 8481

## UPDATED FILING RECEIPT



\*OC000000012731196\*

Date Mailed: 05/20/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

- Suzanne Benedict, Carlsbad, CA;
- Michael Bennett, San Diego, CA;
- Sacha Ninkovic, Carlsbad, CA;
- Min Teng, San Diego, CA;
- Yuanjin Rui, San Diego, CA;
- Fen Wang, San Diego, CA;

RECEIVED  
JUN 01 2004  
LA JOLLA PATENT DEPT

## Assignment For Published Patent Application

Agouron Pharmaceuticals, Inc.;

Domestic Priority data as claimed by applicant: *this application claims priority benefits under 35 U.S.C. 3119(e) of a provisional application Serial No. 60/439,396, filed January 9, 2003.*  
Foreign Applications

If Required, Foreign Filing License Granted: 04/13/2004

Projected Publication Date: 07/14/2005

Non-Publication Request: No

Early Publication Request: No

**Title**

Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

**Preliminary Class**

546

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).